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Interplay between sympathetic 
nervous system and inflammation 
in aseptic loosening of hip joint 
replacement
M. Ribeiro-da-Silva1,2,3,4, D. M. Vasconcelos1,2, I. S. Alencastre1,2, M. J. Oliveira1,2, 
D. Linhares3,4, N. Neves1,2,3,4, G. Costa3,4, R. Henrique5,6, M. Lamghari1,2,6 & C. J. Alves  1,2
Inflammation is a common symptom in joint disorders such as rheumatoid arthritis, osteoarthritis (OA) 
and implant aseptic loosening (AL). The sympathetic nervous system is well known to play a critical 
role in regulating inflammatory conditions, and imbalanced sympathetic activity has been observed 
in rheumatoid arthritis. In AL it is not clear whether the sympathetic nervous system is altered. In this 
study we evaluated the systemic and local profile of neuroimmune molecules involved in the interplay 
between the sympathetic nervous system and the periprosthetic inflammation in hip AL. Our results 
showed that periprosthetic inflammation does not trigger a systemic response of the sympathetic 
nervous system, but is mirrored rather by the impairment of the sympathetic activity locally in the hip 
joint. Moreover, macrophages were identified as key players in the local regulation of inflammation 
by the sympathetic nervous system in a process that is implant debris-dependent and entails the 
reduction of both adrenergic and Neuropetide Y (NPY)-ergic activity. Additionally, our results showed 
a downregulation of semaphorin 3A (SEMA3A) that may be part of the mechanism sustaining the 
periprosthetic inflammation. Overall, the local sympathetic nervous system emerges as a putative 
target to mitigate the inflammatory response to debris release and extending the lifespan of orthopedic 
implants.
Osteoarthritis (OA) is one of the most prevalent chronic joint diseases and a major contributor to functional 
disability and loss of autonomy in older adults1. It is associated with a substantial economic and social burden, 
which will be even higher in the upcoming years, with the expected aging of the population1. Total joint replace-
ment is considered the actual gold standard for the treatment of patients with severe OA, providing pain relieve, 
improving joint function and enhancing patients´ quality of life2,3. Unfortunately, total joint replacements can 
fail, mostly due to periprosthetic inflammation featured by sustained chronic inflammatory response initiated 
by implant degradation products that shed and accumulate in the neighbor tissue4. This adverse tissue reaction 
is orchestrated by a large plethora of immune cells of which the macrophage lineage has been shown to be of 
major relevance4,5. It is well established that macrophage differentiation towards M1 (pro-inflammatory) or M2 
(anti-inflammatory) phenotype is of key importance to the inflammation state and/or resolution. In vitro studies 
have shown that Poly(methyl methacrylate) (PMMA) and ultra-high molecular weight polyethylene (UHMWPE) 
implant particles can polarize macrophages to pro-inflammatory M1 phenotype6–8. The activation of mac-
rophages and other local cells results in the release of pro-inflammatory factors such as cytokines, chemokines, 
prostanoids, degradative enzymes and reactive oxygen species5,9. These factors underlie the chronic inflammatory 
scenario that may lead to painful synovitis, pathologic fracture of the surrounding bone and impaired function, 
instability and loosening of the implant9.
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Over the past decades, accumulating evidence has clearly attributed a pivotal role to the sympathetic nerv-
ous system and its neurotransmitters in the regulation of chronic inflammatory conditions10,11. It has been 
demonstrated that the activation of the sympathetic nervous system in the context of inflammation results in 
the release of high amounts of sympathetic neurotransmitters known to induce an anti-inflammatory effect in a 
context-dependent manner11,12. The immunomodulatory effect of sympathetic nervous system can be achieved 
directly via adrenergic receptors (ADRs) expressed by the immune cells. Two types of ADRs have been charac-
terized, the alpha (A) and beta (B), which were further divided into nine receptors subtypes (A1A, A1B, A1D, 
A2A, A2B, A2C, B1, B2 and B3)13. Stimulation of ADRB2 is reported to activate anti-inflammatory mechanisms 
on immune cells, while stimuli via ADRA activates pro-inflammatory mechanisms14. Therefore, the overall result 
will depend on the ADRs family being activated, which depends on the receptor expression profile and also on 
the norepinephrine concentration (norepinephrine has a high affinity to ADRA, only binding to ADRB when at 
high concentrations)14.
The neuropeptide Y (NPY), a neurotransmitter co-released with norepinephrine by the sympathetic nerve 
fibers, has also been reported to have modulatory effect on the activity of immune cells15. On the context of the 
immune response, of the five NPY receptors, the Y1 receptor (Y1R) is the most well studied, and has been shown 
to have a critical role in immunomodulation, as demonstrated by the attenuation of inflammation in Y1R knock-
out mice16. In healthy human joints, the synovium is highly innervated with both sympathetic and sensory nerve 
fibers17. In rheumatoid arthritis, data obtained in humans and in animal models revealed a deprivation of neu-
ronal derived neurotransmitters in synovium tissue, due to the loss of sympathetic innervation14,18–20. Moreover, 
the extent of this deprivation is correlated with the severity of the inflammation. In fact, comparative studies 
reported a reduction of sympathetic innervation in synovial tissue of rheumatoid arthritis patients while in OA 
patients this does not occur18. In our previous work, we reported similar absence of sympathetic nerve fibers in 
periprosthetic tissues from AL patients while, again, in OA patients this does not occur21. In this line of evidence, 
the sympathetic activity is affected by the intensity of inflammation in the joint. However, it is still unknown 
whether in debris-associated periprosthetic inflammation occurs a complete shutdown of the sympathetic activity 
without any rescue mechanisms, and if the observed alterations are restricted to the joint or are also reflected at 
systemic level.
In this study we evaluated the systemic and the local profile of neuroimmune molecules involved in the inter-
play between sympathetic nervous system and the inflammatory response to the debris released by hip implants 
in AL. A comparison with OA was performed.
Results
Periprosthetic inflammation does not trigger the activation of the systemic neuroimmune reg-
ulatory pathway. Several studies have shown the activation of the systemic sympathetic nervous system in 
response to pro-inflammatory cytokines as a means to mobilize energy-rich molecules and sustain the inflam-
matory process14. In order to investigate the impact of periprosthetic inflammation on the systemic sympathetic 
nervous system activity, the serum levels of norepinephrine, epinephrine and NPY (markers of sympathetic nerv-
ous system activity) were measured in AL patients, OA patients, and healthy donors. In addition, the serum 
levels of cortisol were also assessed in the same groups as an indicator of the Hypothalamus-Pituitary-Adrenal 
(HPA) axis activity. The HPA axis together with the sympathetic nervous system compose the hormonal pathway 
through which the central nervous system exerts a regulatory control over inflammation14. No differences were 
found in the norepinephrine and NPY serum levels between the three groups (Fig. 1a). Epinephrine levels were 
below the detection limit of the used commercial kit. A tendency of higher cortisol levels was observed in AL 
patients when compared with healthy donors (p = 0.0658), although no statistically significant differences were 
found (Fig. 1a).
The serum levels of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, key players in the activation of 
the sympathetic nervous system and HPA axis in response to inflammation14, were also measured in AL and OA 
patients and in healthy donors. The blood levels of IL-6 were higher in AL and OA patients than in healthy donors 
(p < 0.001 and p < 0.01, respectively) (Fig. 1b). The levels of IL-1β and TNF-α were observed to be below the 
ELISA kits’ detection limits in all groups.
Normal cortisol serum levels in the presence of high IL-6 concentrations are indicative of an inadequate cor-
tisol secretion22, and the ratio serum cortisol/IL-6 was shown to be the more suitable indicator of the HPA axis 
activity23. Therefore, to further evaluate the HPA axis activity, the ratio of serum cortisol / IL-6 was calculated. 
Results showed no differences in this ratio between the groups, although a not statistically significant trend to 
lower values was observed in AO patients when compared with healthy donors (p = 0.0517) (Fig. 1c).
Local sympathetic response is impaired in macrophages in periprosthetic tissues from AL 
patients. Locally, the sympathetic nervous system is known to modulate the inflammatory response through-
out adrenergic and NPY-ergic signaling14. In order to explore the effect of the sustained release of debris from 
implants on the local sympathetic immune-regulation, the expression of tyrosine hydroxylase (TH), ADRA1, 
ADRA2A, ADRB2, NPY and Y1R was analyzed in macrophages, B and T cells. A comparison between peripros-
thetic tissues and OA synovial tissues was performed. Macrophages in OA synovial tissues were found to express 
TH, ADRA1 and ADRB2, but not the macrophages present in periprosthetic tissues (Fig. 2a). ADRA2A was 
expressed by macrophages in both tissues (Fig. 2a). Macrophages in OA synovial tissues also stained positively 
for NPY but not macrophages in AL tissues (Fig. 2b).
Interestingly, the activation of ADRB2 in macrophages has been shown to promote a preferential differenti-
ation of macrophages towards anti-inflammatory M2 phenotype over the pro-inflammatory M1 phenotype24. 
However, to our knowledge, the expression profile of ADRB2 in M1 and M2 macrophages was never described. 
Here we show that in vitro macrophages display a lower ADRB2 mRNA expression levels in M1 than in M2 
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phenotypes (p < 0.05) (Fig. 3). The in vitro analysis of ADRA1 and ADRA2 mRNA expression in M1 and M2 
macrophages showed very low expression values, which were in some samples even below the detection limit. 
Still, from the results obtained, no differences were found in the ADRA1 and ADRA2 mRNA expression between 
M1 and M2 macrophages (data not shown).
T cells were found to express ADRA1 both in periprosthetic tissues and OA synovial membrane, but not 
ADRA2A and ADRB2 (Fig. 4a). T cells were also expressing TH in OA but not in AL tissues. B cells were not 
expressing the adrenergic markers investigated neither in AL nor in OA (Fig. 5a) and the expression of NPY and 
Y1R was absent from T and B cells in both pathologic conditions (Figs 4b and 5b).
The absence of sympathetic innervation in periprosthetic tissues from AL patients is not medi-
ated by the classic regulators of the innervation pattern. In our previous work21, using the same 
samples that were used in this study, we reported an unbalanced innervation pattern in hip periprosthetic tis-
sues, mirrored by the lack of sympathetic nerve fibers. Here, in order to investigate the molecular mechanism 
underlying this effect, we evaluated the mRNA expression of the classical neurotrophins NGF and BDNF, of the 
nerve repellent molecule SEMA3A, and of the sympathetic nerve repellent factors SEMA3C and SEMA3F in the 
AL and OA joint tissues. No differences were found in the mRNA expression levels of NGF and BDNF between 
periprosthetic tissues and OA synovial membrane (Fig. 6a). Interestingly, the mRNA levels of SEMA3A, SEMA3C 
and SEMA3F were found to be decreased in periprosthetic tissues when compared with OA synovial tissues 
(SEMA3A: p < 0.01; SEMA3C and SEMA3F: p < 0.05) (Fig. 6b).
Discussion
In this study we show that the periprosthetic inflammatory response is not decoded by the sympathetic nervous 
system at systemic levels, but is mirrored locally in the hip joint by the impairment of adrenergic and NPY-ergic 
activity in macrophages.
Pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 released by local immune cells were identified as 
key players in the central activation of sympathetic nervous system14. Moreover, implant debris were shown to 
promote the in vitro release of pro-inflammatory cytokines by lymphocytes25 and macrophages26, and in OA an 
increase of TNF-α in synovial membrane and blood, and of IL-6 in synovial fluid and blood was reported27. In 
this study, the comparison of the IL-1β, IL-6 and TNF-α profile showed an increase in the serum levels of IL-6 
in both AL and OA patients (in comparison with healthy donors) but no differences between AL and OA. Such 
results highlight IL-6 as a main mediator of the systemic inflammatory response in the studied joint disorders. 
Still, these increased blood levels of IL-6 were not reflected in an increased systemic sympathetic tone neither in 
AL nor in OA patients, suggesting that the inflammatory response is not being regulated by the systemic sympa-
thetic nervous system, even in scenarios where debris is being released. Moreover, the evaluation of the cortisol 
blood levels and the analysis of the cortisol/ serum IL-6 ratio, strong indicators of HPA axis activity23, showed 
no significant differences between the three analyzed groups, suggesting no impact in the HPA axis activity. The 
Figure 1. The systemic neuroimmune regulatory pathway was not targeted by periprosthetic inflammation 
in AL patients. The levels of norepinephrine, NPY and cortisol (a) and the levels of IL-6 (b) were evaluated by 
ELISA in the serum collected pre-operatively from OA and AL patients, and from healthy donors. The ratio 
serum cortisol/IL-6 was calculated (c). Results are presented as mean ± SEM, n = 13–15 for healthy donors and 
AO patients and n = 14–20 for AL patients. **p < 0.01; ****p < 0.001.
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combined lack of activation of the systemic sympathetic nervous system and the HPA axis supports the absence 
of a systemic control of the inflammatory reaction in both OA and AL conditions.
Within the inflammation site, sympathetic nervous system can directly influence immune cells via the ADRs 
expressed on their cell surface28. The sympathetic immunomodulatory effects are known to be dependent on 
parameters such as the ADRs profile and the catecholamines concentration. The stimulation of ADRA, sensi-
tive to low concentrations of norepinephrine, activates pro-inflammatory mechanisms, while ADRB2 activation 
by high concentrations of norepinephrine, triggers anti-inflammatory processes14. The sympathetic influence 
on immune function can also be exerted by other neurotransmitters co-released with norepinephrine, such as 
NPY15. In order to understand the impact of the debris release in the local sympathetic control of the inflamma-
tory response we investigated both the adrenergic and the NPY-ergic activity in immune cells. In the follow up of 
our previous work21, the expression of TH, ADRA1, ADRA2A and ADRB2 (adrenergic markers) and of NPY and 
Figure 2. Macrophages in AL periprosthetic tissues do not express TH or ADRB2. The expression of TH, 
ADRA1, ADRA2A and ADRB2 (a) and the expression of NPY and Y1R (b) by macrophages (CD68+) 
was evaluated in periprosthetic tissues from AL patients and in synovial tissues from OA patients through 
double immunohistochemistry staining. Macrophages expressing TH, ADRA1, ADRA2A, ADRB2 or NPY 
are highlighted with triangle head white arrows. Simple head white arrows indicate macrophages and white 
arrowheads highlight TH, ADRA1, ADRB2, NPY and Y1R staining in cells other than macrophages (positive 
control). Scale bar = 20 μm.
www.nature.com/scientificreports/
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Y1R (NPY-ergic markers) in macrophages, B and T cells, the main immune cell types previously identified in AL 
periprosthetic tissues and in OA synovial membrane21, were investigated by immunohistochemistry.
Our immunostaining results showed that TH, ADRA1, ADRB2 and NPY were expressed by macrophages 
in OA synovial tissues but are absent in macrophages from periprosthetic tissues. These results show that both 
the adrenergic and the NPY-ergic arms are implicated in the local regulation of joint inflammation by the sym-
pathetic nervous system in a debris-dependent manner and reinforce macrophages as key cellular players in the 
process. Moreover, the absence of TH and ADRB2 in AL macrophages suggests a lack of sympathetic-mediated 
anti-inflammatory mechanisms in response to periprostetic inflammation. It was demonstrated that the stim-
ulation of ADRB2 in macrophages promotes their differentiation towards an M2 anti-inflammatory profile 
and serves as a mean to prevent hyper-inflammation24. In addition, the pro-inflammatory M1 macrophages 
are increased in AL periprosthetic tissues when compared with OA synovial membrane6, and in vitro stud-
ies showed that PMMA and UHMWPE implant particles promoted macrophages polarization towards a M1 
pro-inflammatory phenotype6–8. In our study we observed that only OA macrophages, and not AL macrophages 
expressed ADRB2. Hence, we decided to assess whether macrophages polarization in M1 or M2 could impact 
the ADRB2 expression profile. For this aim, an in vitro experiment exploring ADRB2 expression in M1 and M2 
macrophages was performed. The results showed that the expression of ADRB2 is lower in M1 pro-inflammatory 
phenotype than in M2 anti-inflammatory phenotype macrophages, suggesting that the lack of ADRB2 observed 
in macrophages in AL tissues might be involved in the harshness of the periprosthetic inflammation.
ADRA were also found to be differentially expressed in OA and AL macrophages (in OA both ADRA1 
and ADRA2A are present while in AL only ADRA2A were found) suggesting a debris-dependent activity of 
ADRA-mediated macrophages pro-inflammatory mechanisms. Very limited research is available on ADRA 
expression profile and function in macrophages29. Whether such different expression profile is a direct conse-
quence of the presence of debris, and/or conditions the different inflammatory outcomes is not known and should 
be further investigated.
Regarding NPY-ergic regulation, NPY produced by immune cells during inflammation is known to modulate 
the cellular activity through autocrine or paracrine actions15,30. NPY has been shown to decrease the expression 
of the pro-inflammatory TNF-α by macrophages after stimulation with LPS31 and to increase the expression of 
the anti-inflammatory TGF-β132, contributing to ameliorate the inflammatory response. Moreover, it was recently 
suggested that NPY promotes the differentiation of macrophages towards a M2 anti-inflammatory phenotype33. 
Based on this information, and in the same way to what was found for ADRB2, the observed lack of NPY expres-
sion in AL macrophages may induce a preferential differentiation towards a pro-inflammatory phenotype. Such 
increase in the M1/M2 ratio may underlie the perpetuation of inflammation and increased osteolysis leading to 
implant failure. Although several immunomodulatory roles of NPY were suggested to occur through Y1R15, the 
expression of this receptor was not observed neither in macrophages in periprosthetic tissues nor in OA synovial 
membrane, hence, other NPY receptors (namely Y2R and Y5R) might be involved in the NPY regulation of mac-
rophages activity30,34.
In regard to the B and T cells, we have previously shown that they are present in low number in both AL and 
OA tissues, and no differences in their population densities between the two joint conditions were found21. The 
activity of B and T cells has been reported to be modulated by the sympathetic nervous system, mostly through 
the ADRB235. The sympathetic modulatory effects seem to be dependent on (i) the activation and differentiation 
state of the cells, on (ii) the molecular signalling pathway activated, and on (iii) the cytokine microenvironment35. 
In this study, we found that T cells and B cells were not expressing ADRB2 neither in AL nor in OA tissues, sug-
gesting an absence of ADRB2 modulation of these cells populations. Moreover, B cells were also not expressing 
any of the investigated ADRA neither in OA nor in AL tissues indicating that these receptors are not involved in 
the regulation of these cells activity by the sympathetic nervous system. It was found that ADRA1 is expressed in 
T cells, both in OA and AL. This receptor has been described as an inhibitor of T cells proliferation36. Through 
Figure 3. The in vitro expression of ADRB2 is lower in M1 as compared with M2 macrophages. The in 
vitro mRNA expression of ADRB2 was evaluated in M0, M1 and M2 macrophages phenotypes. Results are 
represented as mean ± SEM, for n = 5 per group. Each symbol represents macrophages obtained from one 
specific blood donor. *p < 0.05.
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our results, that show the expression of ADRA1 by mature T cells (CD3+) in both AL and OA tissues, a different 
putative role of ADRA1 in T cells-mediated inflammation, other than the inhibition of proliferation, which is 
independent of particles released by the implants, is suggested. As observed in macrophages, T cells were found 
to express TH in OA but not in AL tissues, supporting the higher ability of non-neuronal synthesis of catechola-
mines in OA synovial membrane when compared to AL periprosthetic tissues.
Evidence showed a repulsion of sympathetic nerve fibers from inflamed tissues that cause the loss of 
anti-inflammatory neurotransmitters and allow the establishment of a privileged pro-inflammatory area18,37–39. 
In a previous work, performed in the same samples used in the present study, we have also reported the repul-
sion of sympathetic innervation from periprosthetic tissues in AL patient but not from synovial membrane in 
OA patients21. Here, we investigate the putative involvement of well-studied neurotrophic factors, NGF and 
BDNF, of the nerve repellent molecule SEMA3A, and of the sympathetic nerve repellent factors SEMA3C and 
SEMA3F in this specific innervation pattern. No differences were found in the expression levels of NGF and 
BDNF between AL periprosthetic tissues and OA synovial membrane. The expression of the chemorepellent 
Figure 4. T cells express ADRA1 both in AL periprosthetic tissues and OA synovial membrane. The expression 
of TH, ADRA1, ADRA2A and ADRB2 (a), and the expression of NPY and Y1R (b) in T cells (CD3+) was 
evaluated in periprosthetic tissues from AL patients and in synovial tissues from OA patients through a double 
immunohistochemistry staining. T cells expressing TH or ADRA1 are highlighted with triangle head white 
arrows. Simple head white arrows indicate T cells and white arrowheads highlight ADRA1, ADRA2A, ADRB2, 
NPY and Y1R staining in cells other than T cells (positive control). Scale bar = 20 μm.
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molecule SEMA3A, SEMA3C and SEMA3F was lower in periprosthetic tissues when compared with OA synovial 
membrane. Such results indicate that the most well studied molecules involved in the modulation of the innerva-
tion pattern were not responsible for the repulsion of the sympathetic innervation from periprosthetic tissues of 
AL patients. Considering that SEMA3A has also been described as having an immunomodulatory role40–42, the 
observed decrease SEMA3A expression may be part of the mechanism underlying the different inflammatory 
profile between OA synovial membrane and periprosthetic tissues. Actually, decreased levels of SEMA3A were 
observed in synovial tissues from rheumatoid arthritis patients compared to synovial tissues in OA patients, and 
the reduction of SEMA3A expression has been correlated with rheumatoid arthritis exacerbation43. Moreover, 
overexpression of SEMA3A reduced inflammation in a mouse model of collagen-induced arthritis44, further 
supporting SEMA3A as an important immunomodulatory molecule.
Overall, in this work we show that periprosthetic inflammation in AL does not trigger a systemic response of 
the sympathetic nervous system but impairs the local sympathetic activity as a putative mean to enable the per-
petuation of the inflammatory state. Macrophages were highlighted as key cellular players in the local regulation 
Figure 5. B cells in AL periprosthetic tissues and OA synovial membrane do not express TH, ADRA1, 
ADRA2A, ADRB2, NPY or Y1R. The expression of TH, ADRB2, ADRA1 and ADRA2A (a), and the expression 
of NPY and Y1R (b) in B cells (CD20+) was evaluated in periprosthetic tissues from AL patients and in synovial 
tissues from OA patients through double immunohistochemistry staining. White arrows indicate B cells and 
white arrowheads highlight positive staining for TH, ADRA1, ADRA2A, ADRB2 and Y1R in cells other than B 
cells (positive control). Scale bar = 20 μm.
www.nature.com/scientificreports/
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of inflammation by the sympathetic nervous system, in a process that is implant debris-dependent and entails the 
reduction of the activity of both the adrenergic and the NPY-ergic systems. The absence of TH, ADRB2 and NPY 
expression in macrophages in periprosthetic tissues from AL patients may underlie a preferential differentiation 
of macrophages towards a M1 pro-inflammatory phenotype, promoting inflammation and increased osteolysis 
that may lead to implant failure. The local sympathetic nervous system emerges, therefore, as a putative target to 
mitigate the inflammatory response to debris release and extending the lifespan of orthopedic implants.
Methods
Samples. Biological samples were collected from three groups of patients. Group 1 was constituted by twenty 
patients (20 hips) undergoing hip revision surgery due to AL, after exclusion of infection, recurrent disloca-
tion and periprosthetic fractures. All patients had a metal-on-polyethylene coupling and eleven prosthesis were 
cemented. All acetabular components were revised and in five of those the femoral stem was also exchanged. In 
four patients metallosis was observed and the mean time to revision was 120.05 ± 65.8 months. Group 2 was 
constituted by fifteen patients (15 hips), submitted to primary hip replacement surgery for primary OA, after 
excluding patients with a known history of inflammatory or neoplastic diseases. Group 3 was constituted by 15 
healthy volunteers (i.e. without known osteoarticular or systemic diseases). Demographics from Groups 1–3 are 
presented in Table 1.
Serum was obtained from the blood collected, during the morning, previously to surgery in Groups 1 and 2, 
and in Group 3, and kept at −80 °C until analyses. Synovial tissue was removed during the surgical procedure in 
Group 2 patients, and periprosthetic tissue was collected in Group 1.
This study was approved by the Ethics Committee of Centro Hospitalar São João and all patients signed an 
informed consent to the use of their samples for research purposes. All the procedures were in accordance with 
the Helsinki Declaration of 1975, as revised in 2000.
ELISA. The levels of Epinephrine/Norepinephrine, NPY and Cortisol were measured in the serum obtained 
from AL patients, OA patients and healthy donors, using ELISA kits from Abcam plc (Cambridge, UK; Catalog 
Number: AB108665), Merck KGaA (Darmstadt, Germany; Catalog Number: EZHNPY-25K) and Abnova 
Figure 6. Neurotrophins and semaphorins expression in AL periprosthetic tissues and OA synovial membrane. 
The mRNA levels of neurotrophins NGF and BDNF (a), and semaphorins SEMA3A, SEMA3C and SEMA3F (b) 
were assessed in OA synovial membrane and periprosthetic tissues from AL patients. Results are represented as 
mean ± SEM, for n = 8–9 per group. **p < 0.01, *p < 0.05.
N
Age (years) Gender
Mean (±SD) p N of male/female p
Group 1 Revision Surgery due to AL 20 70.35 ± 11.4 0.119 6/14
0.537
Group 2 Primary Surgery due to OA 15 63.33 ± 14.5 6/9
Group 3 Healthy Donors 15 32.87 ± 3.4  < 0.001* 9/6
Table 1. Demographic data on included patients. AL- Aseptic loosening; OA- Osteoarthritis. *Comparing 
Group 3 with both Group 1 and Group 2.
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(Taoyuan, Taiwan; Catalog Number: KA1877) respectively, according to the manufacturers’ protocols. The serum 
levels of interleukin (IL)-1β, IL-6 and Tumor necrosis factor alpha (TNF-α) were also measured in the same 
groups, using ELISA kits from BioLegend (CA, USA; Catalog Number: 430507).
Monocyte isolation and macrophage differentiation. Human monocytes were isolated from healthy 
blood donors and differentiated into macrophages45. Briefly, 106 monocytes/mL/3,8 cm2 were cultured for 10 days 
in RPMI1640 medium, supplemented with 10% Fetal bovine serum (FBS) and 100 U/mL penicillin and 100 μg/
mL streptomycin, in the absence of Macrophages colony-stimulating factor (M-CSF) or other exogenous factors. 
10 ng/mL LPS (Sigma-Aldrich) or IL-10 (ImmunoTools, Friesoythe, Germany) were added, for additional 72 h, to 
polarize macrophages towards M1 or M2 phenotype, respectively. Unstimulated macrophages (M0) were main-
tained with renewed medium.
Double immunofluorescence staining. The expression of markers of the sympathetic nervous system by 
immune cells (macrophages, B cells and T cells) was evaluated through a double immunofluorescence staining 
analysis. The collected tissues were formaldehyde-fixed and processed for paraffin embedding, and cross-sections 
of 3 μm thickness were cut in the microtome (RM2255, Leica Biosystems). Deparaffinized and dehydrated sec-
tions were placed in antigen retrieval for 20 min at 97 °C (10 mM citrate buffer, pH 6.0). After quenching endoge-
nous fluorescence with 0.1% NaBH4 and 100 mM NH4Cl, sections were incubated with blocking buffer (10% FBS, 
1% Bovine serum albumin (BSA), 0.2% Triton X-100).
Simultaneous incubation of each primary antibody against immune cells (antibodies mouse anti-CD68 (clone 
514H12, dilution 1:100, Novocastra, UK), anti-CD20 (clone L26, dilution 1:100, Cell Marque, USA), anti-CD3 
(clone PS1, dilution 1:100, Biocare Medical, USA)) with each primary antibody against sympathetic markers 
(antibodies rabbit anti-TH (dilution 1:100, Merck KGaA, Darmstadt, Germany), anti-ADRA1 (dilution 1:100, 
Abcam, USA), anti-ADRA2A (dilution 1:200, Abcam, USA), anti-ADRB2 (dilution 1:100, Proteintech, USA), 
anti-NPY (dilution 1:1000, Sigma-Aldrich, USA) or anti-Y1R (dilution 1:500, Immunostar, USA)) were per-
formed overnight at 4 °C.
For signal detection, tissue sections were incubated for 1 hour at room temperature (RT) with a mix-
ture of anti-rabbit Alexa Fluor 568 antibody and anti-mouse Alexa Fluor 488 antibody (1:1000 dilution, Life 
Technologies, USA), incubated with DAPI and then mounted with Fluoroshield Mounting Medium (Abcam, 
USA). Immunostaining images were acquired on the confocal Leica TCS SP2 AOBS (Leica Microsystems, 
Germany) and Leica TCS SP5 microscope (Leica Microsystems, Germany).
Gene expression analysis. Synovial tissues were homogenized in liquid nitrogen using a mortar and pestle 
to preserve RNA integrity. RNA from synovial tissues and from macrophages was extracted and purified using 
TRIzol (Invitrogen, UK) and Direct-zol™ RNA MiniPrep (ZYMO Research, USA), according to the manufac-
turers’ instructions.
RNA purity was estimated from the ratio of absorbance readings at 260 and 280 nm and only ratio between 
1.8 and 2 were accepted. RNA quality was verified in agarose gel and RNA concentration was determined in a 
NanoDrop spectrophotometer (NanoDrop™ 1000 Spectrophotometer, Thermo Fisher Scientific, Wilmington, 
Delaware, USA NanoDrop). RNA was reverse transcribed using the SuperScriptTM First-Strand Synthesis System 
for reverse transcription-polymerase chain reaction (RT-PCR) (Invitrogen, Carlsbad, CA, USA).
The transcriptional levels of ADRA1A, ADRA1B, ADRA1D, ADRA2A and ADRB2 in macrophages and neuro-
trophins (Nerve growth factor (NGF) and Brain-derived neurotrophic factor (BDNF)) and semaphorins (SEMA3A, 
SEMA3C and SEMA3F) in the AL and OA tissues were evaluated by quantitative real time PCR (qRT-PCR) in the 
CFX96 Touch Detection System (Bio-rad, USA). β2 microglobulin (B2M) was used as reference gene for internal 
normalization. The primers used were as follows: ADRA1A sense primer: 5′-TCATGTACTGCCGCGTCTAC-3′; 
ADRA1A antisense primer: 5′-GGGCGTTTTTCCGATGGATG-3′; ADRA1B sense primer: 5′-CTCTACCGCTT 
GGCTCCTTGT-3′; ADRA1B antisense primer: 5′-GGAGCATGGGTAGATGATGGG-3′; ADRA1D sense primer: 
5′-TCTCCCGTGAGAAGAAAGCG-3′; ADRA1D antisense primer: 5′-CGGGAACAAGGAGCCGAG-3′; ADR 
A2A sense primer: 5′-ATCCTGGCCTTGGGAGAGAT-3′; ADRA2A antisense primer: 5′-TCTCAAAGCAGG 
TCCGTGTC-3′; ADRB2 sense primer: 5′GGACTTCCATTGATGTGCTGT-3′; ADRB2 antisense primer: 5′-GTCA 
GCAGGCTCTGGTACTTG-3′; NGF sense primer: 5′-AGCGCAGCGAGTTTTGG-3′; NGF antisense primer: 
5′-GCTGCTCCCTTGGTAAACTG-3′; BDNF sense primer: 5′- GATGCTCAGTAGTCAAGTGCC-3′; BDNF 
antisense primer: 5′-GCCGTTACCCACTCACTAATAC-3′; SEMA3A sense primer: 5′CAGCCATGTACAAC 
CCAGTG-3′; SEMA3A antisense primer: 5′-ACGGTTCCAACATCTGTTCC-3′; SEMA3C sense primer: 
5′-ATCCGGTCCTGATCTTCATC-3′; SEMA3C antisense primer: 5′-CAGCCCCAAGCAAGAGTTTA-3′; 
SEMA3F sense primer: 5′-CCAACTACCAGTGGATGCCC-3′; SEMA3F antisense primer: 5′-GTACACGG 
CCTGGTACATGA-3′; B2M sense primer: 5′-CCAGCGTACTCCAAAGATTCAG-3′; B2M antisense primer: 5′- 
AGTCAACTTCAATGTCGGATGG-3′. Relative transcription levels were calculated by comparative threshold 
cycle quantification (ΔCt method) using B2M as reference gene.
Statistical analyses. All data were assessed for normal distribution and non-parametric analyses were per-
formed whenever normal distribution was not followed. Hormones and IL-6 levels, and the cortisol/IL-6 ratio 
were analyzed by Kruskal-Wallis test followed by Dunn’s multiple comparison test. mRNA expression of neutro-
phins and semaphorins in the synovial tissues was analyzed by Mann-Whitney test and ADRs mRNA expres-
sion in macrophages by the Repeated Measures ANOVA followed by Holm-Sidak’s multiple comparisons test. 
Differences were considered at the significant level of p < 0.05. All data are expressed as mean ± SEM. Statistical 
analyses were performed using the software Prism 6 (GraphPad software, San Diego, CA, USA).
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